Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Pancreatic Neuroendocrine Neoplasms
- 1Department of Digestive Tract Surgery, Medical University of Silesia, Medyków 14 Street, 40-752 Katowice, Poland
Abstract
Background: Pancreatic neuroendocrine neoplasms (PNENs) represent a rare, heterogeneous group of tumors with highly variable clinical outcomes. While standard clinicopathological parameters like World Health Organization (WHO) grading and TNM staging provide critical prognostic data, they do not fully explain the survival disparities observed in patients with similar tumor characteristics. This narrative review evaluates the clinical and prognostic significance of the neutrophil-to-lymphocyte ratio (NLR)—a widely accessible marker of systemic inflammation—in patients with PNENs. Methods: A comprehensive literature review was conducted to synthesize current evidence regarding the prognostic utility of peripheral NLR levels. Results: Studies conducted specifically in pancreatic neuroendocrine tumors (PNETs) suggest that elevated peripheral blood NLR is associated with adverse clinicopathological features and, in several cohorts, with shorter overall survival (OS) and recurrence-free survival (RFS). However, the strength and independence of these associations vary across studies. Evidence from mixed gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) cohorts undergoing systemic treatment or peptide receptor radionuclide therapy (PRRT) provides complementary insights into the predictive capacity of NLR regarding treatment response, though it remains indirect evidence for PNETs, particularly when pancreatic-specific subgroup results are unavailable. Differences in tumor differentiation, grade, stage, treatment setting, and NLR cut-off values limit direct comparisons across studies. Conclusions: NLR is an accessible, candidate adjunctive prognostic biomarker in PNETs, particularly in surgically treated populations. However, the evidence remains highly heterogeneous, and its clinical utility and standardized thresholds remain unvalidated. Proposed applications in treatment selection or surveillance intensity should be strictly regarded as investigational and hypothesis-generating, rather than validated clinical strategies. NLR should complement, rather than replace, established clinicopathological prognostic factors.
Related
- Joint neutrophil-to-lymphocyte ratio-systemic inflammation response index score as an independent prognostic biomarker for immunotherapy-treated intrahepatic cholangiocarcinoma.
- Beyond Prognosis: A Systematic Review of the Neutrophil-to-Lymphocyte Ratio as a Modifiable Cardiovascular Biomarker
- Prognostic value of the neutrophil-to-lymphocyte ratio in patients with colorectal cancer undergoing chemotherapy: a systematic review and meta-analysis
- Admission blood glucose and neutrophil-to-lymphocyte ratio provide independent and complementary prognostic value for in-hospital mortality in acute type A aortic dissection
- Prognostic value of neutrophil-to-lymphocyte ratio in nasopharyngeal carcinoma: a systematic review and meta-analysis of 30 cohorts through June 30, 2026
BibTeX
@article{jablonska2026neutrophiltolymphocyte,
title = {{Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Pancreatic Neuroendocrine Neoplasms}},
author = {Beata Jabłońska},
journal = {Cancers},
year = {2026},
month = oct,
doi = {10.3390/cancers18213427},
url = {https://www.mdpi.com/2072-6694/18/21/3427},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker in Pancreatic Neuroendocrine Neoplasms
AU - Beata Jabłońska
PY - 2026
DA - 2026/10/22
JO - Cancers
DO - 10.3390/cancers18213427
UR - https://www.mdpi.com/2072-6694/18/21/3427
AB - Background: Pancreatic neuroendocrine neoplasms (PNENs) represent a rare, heterogeneous group of tumors with highly variable clinical outcomes. While standard clinicopathological parameters like World Health Organization (WHO) grading and TNM staging provide critical prognostic data, they do not fully explain the survival disparities observed in patients with similar tumor characteristics. This narrative review evaluates the clinical and prognostic significance of the neutrophil-to-lymphocyte ratio (NLR)—a widely accessible marker of systemic inflammation—in patients with PNENs. Methods: A comprehensive literature review was conducted to synthesize current evidence regarding the prognostic utility of peripheral NLR levels. Results: Studies conducted specifically in pancreatic neuroendocrine tumors (PNETs) suggest that elevated peripheral blood NLR is associated with adverse clinicopathological features and, in several cohorts, with shorter overall survival (OS) and recurrence-free survival (RFS). However, the strength and independence of these associations vary across studies. Evidence from mixed gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) cohorts undergoing systemic treatment or peptide receptor radionuclide therapy (PRRT) provides complementary insights into the predictive capacity of NLR regarding treatment response, though it remains indirect evidence for PNETs, particularly when pancreatic-specific subgroup results are unavailable. Differences in tumor differentiation, grade, stage, treatment setting, and NLR cut-off values limit direct comparisons across studies. Conclusions: NLR is an accessible, candidate adjunctive prognostic biomarker in PNETs, particularly in surgically treated populations. However, the evidence remains highly heterogeneous, and its clinical utility and standardized thresholds remain unvalidated. Proposed applications in treatment selection or surveillance intensity should be strictly regarded as investigational and hypothesis-generating, rather than validated clinical strategies. NLR should complement, rather than replace, established clinicopathological prognostic factors.
SN - 2072-6694
ER -